Latest News!
Research and development lab set up, preliminary mescaline synthesis completeModified synthesis process developed, mescaline batches manufacturedDevelopment of analytical methods and validation, GMP standard operating procedures...
Read Full Story
Featured, News, Press Releases
May 20, 2021
Rapid 25-minute point-of-care COVID-19 PCR test available for purchase in Germany commencing May 25, 2021Volume based pricing competitive with other COVID-19 PCR test products on...
May 13, 2021
Rotigotine transdermal human pilot study successfully completed; program advancing to pivotal studyLand purchased for construction of commercial drug manufacturing facility in Germany Vancouver, Canada, and...
May 7, 2021
Pilot project includes point-of-care sample collection, PCR processing and final testing of workflow logisticsProject is in cooperation with a German pharmacy currently running a COVID-19...
Apr 28, 2021
XPhyto delivered 2,000 of its 25-minute PCR tests to Israeli distributor for clinical evaluation and regulatory approval. Potential customers include government institutions, private healthcare providers...
Apr 21, 2021
XPhyto has entered into an agreement with an established German pharmaceutical wholesaler and service provider for the distribution, storage and logistics of XPhyto's diagnostic products...
Apr 20, 2021
XPhyto announces the appointment of Mr. Wolfgang Probst as the Chief Operations Officer (COO) of XPhyto and the addition of Mr. Manfred Buchberger as the...
Mar 18, 2021
CE Mark received for in vitro diagnostic (IVD) test for the detection of SARS-CoV-2Rapid results with ease of use - single 20-minute PCR cycle plus...
Mar 10, 2021
Vancouver, Canada (March 10, 2021) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”), and its exclusive German diagnostics development partner,...
Mar 4, 2021
Vancouver, Canada (March 4, 2021) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”), is pleased to announce that the Company...
Feb 26, 2021
VANCOUVER, British Columbia – February 26, 2021 – XPhyto Therapeutics Corp. (CSE: XPHY; OTC: XPHYF; FSE: 4XT) (“XPhyto” or the “Company”) at the request of...
Feb 24, 2021
Vancouver, Canada (February 24, 2021) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”), is pleased to announce that it has...
Feb 22, 2021
Vancouver, Canada (February 22, 2021) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”), is pleased to announce that the Company...
Hear about our latest research, products, exclusive partnerships & more.